Selonterra: Funding, Investors & Team (Oct 2026)
Selonterra, Inc. is a San Francisco Bay Area venture capital funded Delaware corporation. Selonterra fundamentally transforms therapeutic approaches to neurodegenerative disorders, including Alzheimer’s disease, by a rigorous exploitation of our novel insights into the genetic causes of disease. Selonterra discovered that the altered DNA of genetic variants associated with neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, affect transcription factor binding sites and thereby change the expression of genes nearby. In our Alzheimer’s disease program we develop small molecules that modulate the function of an unexploited, druggable target and will fundamentally change Alzheimer’s disease therapy. We complement our highly relevant extensive experience in start-ups with a global network of specialized collaborator companies and thereby apply state-of-the art technologies to execute our program in a capital efficient way.
Selonterra has raised $5.0M across 2 funding rounds on record, the most recent an undisclosed round of $2.5M announced in Oct 2024.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Selonterra Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Selonterra Funding Rounds
Selonterra raised $2.5M in an undisclosed round announced in Mar 2023.
1.6 years later, an undisclosed round of $2.5M was announced in Oct 2024.
Selonterra Founders and Leadership Team
No contact details are on record for this team yet.
Selonterra Funding Compared to Other Biotechnology Startups
Selonterra's latest round of $2.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Selonterra in Biotechnology and San Mateo
Companies Similar to Selonterra
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Selonterra Funding FAQs
What does Selonterra do?
Selonterra, Inc. is a San Francisco Bay Area venture capital funded Delaware corporation. Selonterra fundamentally transforms therapeutic approaches to neurodegenerative disorders, including Alzheimer’s disease, by a rigorous exploitation of our novel insights into the genetic causes of disease. Selonterra discovered that the altered DNA of genetic variants associated with neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, affect transcription factor binding sites and thereby change the expression of genes nearby. In our Alzheimer’s disease program we develop small molecules that modulate the function of an unexploited, druggable target and will fundamentally change Alzheimer’s disease therapy. We complement our highly relevant extensive experience in start-ups with a global network of specialized collaborator companies and thereby apply state-of-the art technologies to execute our program in a capital efficient way.
How much funding has Selonterra raised?
Selonterra has raised $5.0M across 2 rounds on record. The most recent is an undisclosed round of $2.5M announced in Oct 2024.
When did Selonterra last raise funding?
Selonterra's most recent funding round on record is an undisclosed round of $2.5M, announced in Oct 2024.
Who founded Selonterra?
FundedIQ lists Anne Urfer Buchwalder (Founder) at Selonterra.
Who is the CEO of Selonterra?
Roman Urfer is listed as CEO at Selonterra.
Where is Selonterra headquartered?
Selonterra is based in San Mateo, California, United States.
How many employees does Selonterra have?
Selonterra is in the 1-10 employee band.
How does Selonterra's funding compare to other Biotechnology startups?
Selonterra's latest round of $2.5M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Selonterra Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Selonterra is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.